Overview
Company Does Not Provide H-1B Sponsorship
Signos provides a wearable device paired with an app to help people manage their metabolism and health. The wearable continuously tracks blood sugar and shows trends, while the app uses that data to offer personalized guidance based on how a user responds to food. The product works by collecting real-time glucose data, analyzing it with AI and a large pool of data, and delivering features like meal- and fasting-related tips, predicted glucose responses for meals, exercise suggestions, and alerts when glucose spikes occur. Signos differentiates itself through metabolism-based, personalized recommendations tied to continuous glucose monitoring, plus in-app nutritionist support and predictive meal insights, all delivered through a subscription. Its goal is to help users lose weight, manage blood sugar, and improve overall health by making informed dietary and lifestyle choices.
Work here?Claim your company
Simplify's take
What believers are saying
- In May 2026, Signos raised $20 million from Dexcom, GV, and Blue Cross Blue Shield.
- CNBC reported revenue and users grew tenfold over six months in 2026.
- Dexcom’s direct-to-consumer Stelo channel can expand Signos into employer and health-plan sales.
What critics are saying
- Ozempic and Zepbound compress Signos’s value proposition by offering faster weight loss today.
- Signos depends on Dexcom’s biosensor supply and platform access; a partner shift would cripple distribution.
- If FDA scrutiny tightens around weight-loss claims, Signos loses its core selling point by 2027.
What makes Signos unique
- Signos is the only FDA-cleared OTC CGM platform for weight management, since August 2025.
- Dexcom integration and Stelo distribution give Signos hardware credibility and retail reach.
- Its AI translates glucose, sleep, stress, and meals into personalized weight-loss guidance.
Help us improve and share your feedback! Did you find this helpful?